デフォルト表紙
市場調査レポート
商品コード
1609746

日本のバイオロジクス市場レポート:由来、製品、疾患、製造、地域別、2024年~2032年

Japan Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2024-2032


出版日
発行
IMARC
ページ情報
英文 121 Pages
納期
5~7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.96円
日本のバイオロジクス市場レポート:由来、製品、疾患、製造、地域別、2024年~2032年
出版日: 2024年12月05日
発行: IMARC
ページ情報: 英文 121 Pages
納期: 5~7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本のバイオロジクス市場の市場規模は2023年に483億米ドルに達しました。今後、IMARC Groupは、2024年から2032年の間に12.80%の成長率(CAGR)を示し、2032年までに市場は1,657億米ドルに達すると予測しています。精密医療アプローチへの需要の高まり、希少疾患の治療への注目の高まり、がん、関節リウマチ、多発性硬化症、慢性炎症性疾患などの慢性疾患や複雑な疾患の有病率の上昇が、市場を牽引する主な要因のいくつかです。

本レポートで扱う主な質問

  • 日本のバイオロジクス市場はこれまでどのように推移し、今後どのように推移していくのか?
  • COVID-19が日本のバイオロジクス市場に与えた影響は?
  • 日本のバイオロジクス市場の由来別の内訳は?
  • 日本のバイオロジクス市場の製品別の内訳は?
  • 日本のバイオロジクス市場の疾患別の内訳は?
  • 日本のバイオロジクス市場の製造別の内訳は?
  • 日本のバイオロジクス市場のバリューチェーンにはどのような段階がありますか?
  • 日本のバイオロジクスにおける主な促進要因と課題は何か?
  • 日本のバイオロジクス市場の構造と主要プレーヤーは?
  • 日本のバイオロジクス市場における競合の程度は?

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本のバイオロジクス市場:イントロダクション

  • 概要
  • 市場力学
  • 業界動向
  • 競合情報

第5章 日本のバイオロジクス市場情勢

  • 過去および現在の市場動向(2018~2023年)
  • 市場予測(2024~2032年)

第6章 日本のバイオロジクス市場:由来別の内訳

  • 微生物
  • 哺乳類
  • その他

第7章 日本のバイオロジクス市場:製品別の内訳

  • モノクローナル抗体
  • ワクチン
  • 組み換えタンパク質
  • アンチセンス、RNAi、分子療法
  • その他

第8章 日本のバイオロジクス市場:疾患別の内訳

  • 腫瘍学
  • 免疫疾患
  • 心血管疾患
  • 血液疾患
  • その他

第9章 日本のバイオロジクス市場:製造別の内訳

  • アウトソーシング
  • 社内

第10章 日本のバイオロジクス市場:競合情勢

  • 概要
  • 市場構造
  • 市場プレーヤーのポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第11章 主要企業のプロファイル

第12章 日本のバイオロジクス市場- 業界分析

  • 促進要因・抑制要因・機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第13章 付録

目次
Product Code: SR112024A19698

Japan biologics market size reached US$ 48.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 165.7 Billion by 2032, exhibiting a growth rate (CAGR) of 12.80% during 2024-2032. The growing demand for precision medicine approaches, increasing focus on treating rare diseases, and rising prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, represent some of the key factors driving the market.

Biologics comprise a wide range of pharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and cell-based therapies. They are derived from living organisms or their components, such as cells, proteins, genes, or tissues. They are produced through biotechnological methods, unlike traditional chemical-based drugs that are synthesized through chemical processes. They interact with specific targets in the body to achieve therapeutic effects. They are known for their high specificity and efficacy, often resulting in fewer side effects compared to conventional drugs. They stimulate the immune system to produce an immune response without causing the disease itself, helping to protect individuals from various viruses and bacteria. They can be tailored to specific genetic or molecular characteristics of disease of patient, enabling personalized treatment approaches. They promote tissue regeneration and wound healing and have fewer side-effects as compared to traditional chemical drugs. They aid in treating certain types of cancer by enhancing the immune response of the body against cancer cells. They assist in addressing rare diseases and orphan diseases that affect a small population. They are used to treat, prevent, or manage various medical conditions and diseases. As they improve the quality of life for patients by effectively managing symptoms and slowing disease progression, the demand for biologics is rising in Japan.

Japan Biologics Market Trends:

At present, the increasing prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, among individuals represents one of the major factors contributing to the market growth in Japan. Moreover, the rising usage of biologics, as they reduce the frequency and severity of hospitalizations, is strengthening the growth of the market in the country. Apart from this, the escalating demand for precision medicine approaches is offering a positive market outlook. Additionally, the increasing awareness among patients about the benefits of biologics, such as fewer side effects, reduced hospital stays, and long-lasting therapeutic effects, is providing lucrative growth opportunities to industry investors in Japan. In line with this, the growing demand for immunotherapies and monoclonal antibodies for treating cancer is influencing the market positively. In addition, innovations in bioproduction methods benefit in cost-effective and efficient production of biologics, which is bolstering the growth of the market. Besides this, the rising number of clinical trials for biologics in the country is propelling the market growth. Furthermore, the increasing focus on treating rare diseases among the masses is impelling the market growth. The technological advancement in biotechnology and genomics enhances the discovery and development of novel biologics, which is also supporting the market growth in Japan.

Japan Biologics Market Segmentation:

Source Insights:

  • Microbial
  • Mammalian
  • Others

Product Insights:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi and Molecular Therapy
  • Others

Disease Insights:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

Manufacturing Insights:

  • Outsourced
  • In-House

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan biologics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan biologics market?
  • What is the breakup of the Japan biologics market on the basis of source?
  • What is the breakup of the Japan biologics market on the basis of product?
  • What is the breakup of the Japan biologics market on the basis of disease?
  • What is the breakup of the Japan biologics market on the basis of manufacturing?
  • What are the various stages in the value chain of the Japan biologics market?
  • What are the key driving factors and challenges in the Japan biologics?
  • What is the structure of the Japan biologics market and who are the key players?
  • What is the degree of competition in the Japan biologics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biologics Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Biologics Market Landscape

  • 5.1 Historical and Current Market Trends (2018-2023)
  • 5.2 Market Forecast (2024-2032)

6 Japan Biologics Market - Breakup by Source

  • 6.1 Microbial
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2018-2023)
    • 6.1.3 Market Forecast (2024-2032)
  • 6.2 Mammalian
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2018-2023)
    • 6.2.3 Market Forecast (2024-2032)
  • 6.3 Others
    • 6.3.1 Historical and Current Market Trends (2018-2023)
    • 6.3.2 Market Forecast (2024-2032)

7 Japan Biologics Market - Breakup by Product

  • 7.1 Monoclonal Antibodies
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2018-2023)
    • 7.1.3 Market Forecast (2024-2032)
  • 7.2 Vaccines
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2018-2023)
    • 7.2.3 Market Forecast (2024-2032)
  • 7.3 Recombinant Proteins
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2018-2023)
    • 7.3.3 Market Forecast (2024-2032)
  • 7.4 Antisense, RNAi and Molecular Therapy
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2018-2023)
    • 7.4.3 Market Forecast (2024-2032)
  • 7.5 Others
    • 7.5.1 Historical and Current Market Trends (2018-2023)
    • 7.5.2 Market Forecast (2024-2032)

8 Japan Biologics Market - Breakup by Disease

  • 8.1 Oncology
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2018-2023)
    • 8.1.3 Market Forecast (2024-2032)
  • 8.2 Immunological Disorders
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2018-2023)
    • 8.2.3 Market Forecast (2024-2032)
  • 8.3 Cardiovascular Disorders
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2018-2023)
    • 8.3.3 Market Forecast (2024-2032)
  • 8.4 Hematological Disorders
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2018-2023)
    • 8.4.3 Market Forecast (2024-2032)
  • 8.5 Others
    • 8.5.1 Historical and Current Market Trends (2018-2023)
    • 8.5.2 Market Forecast (2024-2032)

9 Japan Biologics Market - Breakup by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2018-2023)
    • 9.1.3 Market Forecast (2024-2032)
  • 9.2 In-House
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2018-2023)
    • 9.2.3 Market Forecast (2024-2032)

10 Japan Biologics Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Product Portfolio
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Product Portfolio
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Product Portfolio
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Product Portfolio
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Product Portfolio
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Biologics Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix